Welcome to LookChem.com Sign In|Join Free

CAS

  • or

113211-15-7

Post Buying Request

113211-15-7 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

113211-15-7 Usage

Chemical Properties

Pale-Yellow Solid

Uses

Different sources of media describe the Uses of 113211-15-7 differently. You can refer to the following data:
1. 2-(cyclopropylmethoxy)-1H-isoindole-1,3(2H)-dione is used for preparation of phenylaminobenzimidazoles and analogs as MEK inhibitors for the treatment of chronic pain.
2. It is used for preparation of phenylaminobenzimidazoles and analogs as MEK inhibitors for the treatment of chronic pain.

Check Digit Verification of cas no

The CAS Registry Mumber 113211-15-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,3,2,1 and 1 respectively; the second part has 2 digits, 1 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 113211-15:
(8*1)+(7*1)+(6*3)+(5*2)+(4*1)+(3*1)+(2*1)+(1*5)=57
57 % 10 = 7
So 113211-15-7 is a valid CAS Registry Number.

113211-15-7SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name 2-(cyclopropylmethoxy)isoindole-1,3-dione

1.2 Other means of identification

Product number -
Other names 1H-Isoindole-1,3(2H)-dione,2-(cyclopropylmethoxy)

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:113211-15-7 SDS

113211-15-7Relevant articles and documents

Ligand-Enabled β-Methylene C(sp3)?H Arylation of Masked Aliphatic Alcohols

Liu, Luo-Yan,Melillo, Bruno,Schreiber, Stuart L.,Xia, Guoqin,Yu, Jin-Quan,Zhuang, Zhe

supporting information, p. 7783 - 7787 (2020/03/23)

Despite recent advances, reactivity and site-selectivity remain significant obstacles for the practical application of C(sp3)?H bond functionalization methods. Here, we describe a system that combines a salicylic-aldehyde-derived L,X-type directing group with an electron-deficient 2-pyridone ligand to enable the β-methylene C(sp3)?H arylation of aliphatic alcohols, which has not been possible previously. Notably, this protocol is compatible with heterocycles embedded in both alcohol substrates and aryl coupling partners. A site- and stereo-specific annulation of dihydrocholesterol and the synthesis of a key intermediate of englitazone illustrate the practicality of this method.

HETEROCYCLIC COMPOUNDS AS MEK INHIBITORS

-

Page/Page column 21, (2012/09/25)

The invention provides novel substituted heterocyclic compounds represented by Formula I and Formula II, or a pharmaceutically acceptable salt, solvate, polymorph, ester, tauntomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as inhibitors of MEK and are useful in the treatment of inflammatory diseases, cancer and other hyperproliferative diseases. The invention further provides a method of treatment for inflammatory diseases, cancer and other hyperproliferative diseases in mammals, especially humans

NOVEL COMPOUNDS AS RESPIRATORY STIMULANTS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES

-

Page/Page column 101, (2012/06/16)

The present invention includes compositions that are useful in the treatment of breathing control diseases or disorders in a subject in need thereof. The present invention also includes a method of treating a respiratory disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical formulation of the invention, The present invention further includes a method of preventing destabilization or stabilizing breathing rhythm in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical formulation of the invention.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 113211-15-7